Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235

Benzinga Newsdesk www.benzinga.com Negative 89.3%

Neg 89.3% Neu 0% Pos 0%

Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.